A New Treatment Breakthrough for EGFR-mutated Lung Cancer
The chemotherapy-free combination of lazertinib and amivantamab has just been approved as first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC). In this interview, Consultant Seppo W. Langer discusses the mechanism of action, clinical benefits, and the need for patient selection in future treatment strategies.
